Inhalant-Related Psychiatric Disorders Clinical Presentation

  • Author: Guy E Brannon, MD; Chief Editor: Iqbal Ahmed, MBBS, FRCPsych (UK)   more...
 
Updated: Oct 5, 2010
 

History

Persons who abuse inhalants commonly share characteristics that may help identify them as users. While taking the patient's history, determine their diagnosis based on the DSM-IV-TR criteria for inhalant abuse, inhalant dependence, inhalant intoxication, substance intoxication delirium, substance-induced persistent dementia, substance-induced psychotic disorder, substance-induced mood disorder, substance-induced anxiety disorder, and inhalant-related disorder not otherwise specified (NOS). Pay close attention to the signs and symptoms commonly associated with persons who abuse inhalants (see below). Inquire about other drugs of abuse and a family history of drug and alcohol abuse or addiction. The diagnosis is based solely on the history and a very high index of suspicion.

  • Signs and symptoms
    • Chemical smell or odor on breath or body
    • Redness, sores, or spots around the lips or mouth
    • Redness of eyes
    • Runny or red nose
    • Paint stains on clothing or body
    • Nausea or loss of appetite
    • Drunken or dazed appearance
    • Dizziness
    • Irritability, excitability, or anxiety
    • Slow verbal responses in conversation
    • Sudden behavior change
    • Sensitivity to light
    • Sore or irritated throat
    • Rashes or redness on hands
  • Characteristics of persons who abuse inhalants
    • Delinquency
    • Theft and burglary
    • Poor school attendance
    • Frequent suspension and expulsion from school
    • Social outcast
    • Impoverished families or middle-to-upper income status
    • Lack of parental control or guidance
    • Attention deficit
    • Poor academic performance
    • Antisocial personality
    • Depressive disorders
    • Emotional problems (specifically anxiety, depression, and anger)
    • Low self-esteem
    • Peer pressure with drug influence
  • Criteria for inhalant abuse, adapted from the DSM-IV-TR
    • A maladaptive pattern of substance use leading to clinically significant impairment or distress, as manifested by 1 (or more) of the following, occurring within a 12-month period:
      • Recurrent substance use resulting in a failure to fulfill major obligations at work, school, or home
      • Recurrent substance use in situations in which it is physically hazardous
      • Recurrent substance-related legal problems
      • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance
    • Symptoms never meeting criteria for substance dependence for this class of substance
  • Criteria for inhalant dependence, adapted from the DSM-IV-TR - A maladaptive pattern of substance use leading to clinically significant impairment or distress, as manifested by 3 (or more) of the following, occurring at any time in the same 12-month period:
    • Tolerance
      • A need for markedly increased amounts of the substance to achieve intoxication or desired effects
      • Markedly diminished effects with continued use of the same amount of the substance
    • Withdrawal
      • Characteristic withdrawal syndrome for the substance
      • Same (or a closely related) substance taken to relieve or avoid withdrawal symptoms
    • Substance often taken in larger amounts or over longer periods than was intended
    • A persistent desire or unsuccessful effort to reduce or control substance use
    • Significant time spent in activities necessary to obtain the substance or recover from its effects
    • Important social, occupational, or recreational activities are abandoned or reduced because of the substance use
    • Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance
  • Criteria for inhalant intoxication, adapted from the DSM-IV-TR
    • Recent intentional use or short-term high-dose exposure to volatile inhalants
    • Clinically maladaptive behavioral or psychological changes that developed during or shortly after use of or exposure to volatile inhalants
    • Two (or more) of the following signs developing during or shortly after inhalant use or exposure:
      • Dizziness
      • Nystagmus
      • Incoordination
      • Slurred speech
      • Unsteady gait
      • Lethargy
      • Depressed reflexes
      • Psychomotor retardation
      • Tremor
      • Generalized muscle weakness
      • Blurred vision or diplopia
      • Stupor or coma
      • Euphoria
    • Symptoms not due to a general medical condition and not better accounted for by another mental disorder
  • Criteria for substance intoxication delirium, adapted from the DSM-IV-TR
    • Disturbance of consciousness with reduced ability to focus, sustain, or shift attention
    • A change in cognition or the development of perceptual disturbance that is not accounted for by a preexisting, established, or evolving dementia
    • Disturbance occurs over a short period and tends to fluctuate during the course of the day
    • Evidence from the history, physical examination, or laboratory findings of either of the following:
      • Symptoms of (1) disturbance of consciousness with reduced ability to focus, sustain, or shift attention or (2) a change in cognition or the development of perceptual disturbance that is not accounted for by a preexisting, established, or evolving dementia that developed during substance intoxication
      • Medication use etiologically related to the disturbance
  • Criteria for substance-induced persistent dementia, adapted from the DSM-IV-TR
    • Development of multiple cognitive deficits manifested by both (1) memory impairment and (2) one (or more) of the following cognitive disturbances:
    • Cognitive deficit in (1) memory impairment and (2) aphasia, apraxia, agnosia, or disturbance in executive functioning each cause significant impairment in social or occupational functioning and represents a significant decline from a previous level of functioning
    • Deficients do not occur exclusively during the course of a delirium and persist beyond the usual duration of substance intoxication or withdrawal
    • Evidence from history, physical examination, or laboratory findings that deficits are etiologically related to the persistent effects of substance use
  • Criteria for substance-induced psychotic disorder, adapted from the DSM-IV-TR
    • Prominent hallucinations or delusion
    • Evidence from history, physical examination, or laboratory findings of either of the following:
      • Symptoms of prominent hallucinations or delusion developing during or within 1 month of substance intoxication or withdrawal
      • Medication use etiologically related to the disturbance
    • Disturbance not better accounted for by a psychotic disorder that is not substance induced
    • Disturbance does not occur exclusively during the course of a delirium
  • Criteria for substance-induced mood disorder, adapted from the DSM-IV-TR
    • Prominent and persistent disturbance in mood predominates in the clinical picture and is characterized by either (or both) of the following:
      • Depressed mood or markedly diminished interest or pleasure in all, or almost all, activities
      • Elevated, expansive, or irritable mood
    • Evidence from history, physical examination, or laboratory findings of substance intoxication or withdrawal and the symptoms of (1) depressed mood or markedly diminished interest or pleasure in activities and (2) elevated, expansive, or irritable mood developing during or within 1 month of substance intoxication or withdrawal
    • Disturbance not better accounted for by mood disorder that is not substance induced
    • Disturbance does not occur exclusively during the course of a delirium
    • Disturbance causes clinically significant distress or impairment in social, occupational, or other important area of functioning
  • Criteria for substance-induced anxiety disorder, adapted from the DSM-IV-TR
    • Prominent anxiety, panic attacks, obsession, or compulsion predominating in the clinical picture
    • Evidence from history, physical examination, or laboratory findings of either of the following:
      • Symptoms of prominent anxiety, panic attacks, obsession, or compulsion developing during or within 1 month of substance intoxication or withdrawal
      • Medication use etiologically related to the disturbance
    • Disturbance not better accounted for by an anxiety disorder that is not substance induced
    • Disturbance not occurring exclusively during the course of a delirium
    • Disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Criteria for inhalant-related disorder NOS, adapted from the DSM-IV-TR: The inhalant-related disorder NOS category is for disorders associated with the use of inhalants that are not classified as inhalant dependence, inhalant abuse, inhalant intoxication, inhalant intoxication delirium, inhalant-induced persistent dementia, inhalant-induced psychotic disorder, inhalant-induced mood disorder, or inhalant-induced anxiety disorder.
Next

Physical

  • See Lab Studies; however, no specific laboratory results confirm this diagnosis.
  • Perform a detailed neurological evaluation to look for the following:
    • Apathy
    • Impaired judgment
    • Impulsiveness
    • Aggressive behavior
    • Anorexia
    • Nystagmus
    • Depressed reflexes
    • Altered levels of consciousness
    • Disinhibited behaviors
  • In addition, be aware of the signs and symptoms of inhalant abuse when performing the physical examination; for example, look for the following:
    • Amnesia
    • Rashes (particularly around the hand, nose, and mouth, ie, glue-sniffer's rash)
    • Unusual breath odors (eg, chemical smells)
    • Red or irritated eyes, throat, lungs, and nose
    • Burns
Previous
Next

Causes

Much speculation exists on the cause of inhalant abuse. Its popularity appears to be based on the fact that the substances are easily accessible to young people. The products used are fairly easy to hide, fairly inexpensive, easily attainable, and, for the most part, legal. Therefore, inhalants are readily becoming the drugs of choice. Many adolescents are becoming interested in the instant gratification huffing offers, while others engage in huffing merely because their friends are doing it. However, one subgroup of young people who abuse inhalants do so because they have seen their parents or older siblings abuse illegal drugs, and these young people have decided that huffing is the activity they choose to begin their drug use and addiction.

Previous
 
 
Contributor Information and Disclosures
Author

Guy E Brannon, MD  Associate Clinical Professor of Psychiatry, Louisiana State University Health Sciences Center; Director, Adult Psychiatry Unit, Chemical Dependency Unit, Clinical Research, Brentwood Behavior Health Company

Guy E Brannon, MD is a member of the following medical societies: American Medical Association, American Medical Writers Association, American Psychiatric Association, American Society of Addiction Medicine, Association of Clinical Research Professionals, Louisiana State Medical Society, and Southern Medical Association

Disclosure: AstraZeneca Grant/research funds Other; Janssen Grant/research funds Other; Pfizer Honoraria Speaking and teaching; Sunovion Honoraria Speaking and teaching; Eli Lilly Grant/research funds Other; Forrest Grant/research funds Other

Coauthor(s)

Jennifer M Thomas, MS, MA  Clinical Research Coordinator, Louisiana Clinical Research, LLC

Jennifer M Thomas, MS, MA is a member of the following medical societies: Psi Chi

Disclosure: Nothing to disclose.

Specialty Editor Board

Barry I Liskow, MD  Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Residency Program, University of Kansas School of Medicine; Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Harold H Harsch, MD  Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin

Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: lilly Honoraria Speaking and teaching; Forest Labs None None; Pfizer Grant/research funds Speaking and teaching; Northstar None None; Novartis Grant/research funds research; Pfizer Honoraria Speaking and teaching; Sunovion Speaking and teaching; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research; Merck Honoraria Speaking and teaching

Chief Editor

Iqbal Ahmed, MBBS, FRCPsych (UK)  Faculty, Department of Psychiatry, Tripler Army Medical Center; Clinical Professor of Psychiatry, Clinical Professor of Geriatric Medicine, University of Hawaii, John A Burns School of Medicine

Iqbal Ahmed, MBBS, FRCPsych (UK) is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, American Psychiatric Association, American Society of Clinical Psychopharmacology, and Royal College of Psychiatrists

Disclosure: Nothing to disclose.

References
  1. Takagi MJ, Yücel M, Lubman DI. The dark side of sniffing: paint colour affects intoxication experiences among adolescent inhalant users. Drug Alcohol Rev. Jul 2010;29(4):452-5. [Medline].

  2. Youth Use of Inhalants and Aerosols - State Laws 2010. National Conference of State Legislatures. Available at http://www.ncsl.org/default.aspx?tabid=16447.

  3. Howard MO, Perron BE, Sacco P, Ilgen M, Vaughn MG, Garland E. Suicide ideation and attempts among inhalant users: results from the national epidemiologic survey on alcohol and related conditions. Suicide Life Threat Behav. Jun 2010;40(3):276-86. [Medline].

  4. Sakai JT, Hall SK, Mikulich-Gilbertson SK, Crowley TJ. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry. Sep 2004;43(9):1080-8. [Medline].

  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). 4th ed. Washington, DC: APA Press; 2000:257-64.

  6. National Inhalant Prevention Coalition. National Inhalant Prevention Coalition Web Site. Available at www.inhalants.org. Accessed Feb 4, 2008.

  7. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: Trends in Adolescent Inhalant Use: 2002 to 2007. March 16, 2009. Available at http://www.eric.ed.gov/PDFS/ED504728.pdf.

  8. Kay J, Lieberman JA, Tasman A. Inhalant Use Disorders. In: Psychiatry: behavioral science and clinical essentials. 1st. Philadelphia, Penn: WB Saunders Company; 2000:263-269.

  9. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2006. Youth Violence and Illicit Drug Use. U.S. Department of Health and Human Services. Available at http://www.oas.samhsa.gov/2k6/youthViolence/youthViolence.htm.

  10. Balster RL. Neural basis of inhalant abuse. Drug Alcohol Depend. Jun-Jul 1998;51(1-2):207-14. [Medline].

  11. Cheong R, Wilson RK, Cortese IC, Newman-Toker DE. Mothball withdrawal encephalopathy: case report and review of paradichlorobenzene neurotoxicity. Subst Abus. Dec 2006;27(4):63-7. [Medline].

  12. Courser MW, Holder HD, Collins D, Johnson K, Ogilvie K. An evaluation of retail outlets as part of a community prevention trial to reduce sales of harmful legal products to youth. Eval Rev. Aug 2007;31(4):343-63. [Medline].

  13. Deas D, Brown ES. Adolescent substance abuse and psychiatric comorbidities. J Clin Psychiatry. Jul 2006;67(7):e02. [Medline].

  14. Dinwiddie SH. Abuse of inhalants: a review. Addiction. Aug 1994;89(8):925-39. [Medline].

  15. Doogue M, Barclay M. Death due to butane abuse--the clinical pharmacology of inhalants. N Z Med J. Nov 11 2005;118(1225):U1732. [Medline].

  16. Edwards RW, Stanley L, Plested BA, Marquart BS, Chen J, Thurman PJ. Disparities in young adolescent inhalant use by rurality, gender, and ethnicity. Subst Use Misuse. 2007;42(4):643-70. [Medline].

  17. Espeland K. Identifying the manifestations of inhalant abuse. Nurse Pract. May 1995;20(5):49-50, 53. [Medline].

  18. Flanagan RJ, Ives RJ. Volatile substance abuse. Bull Narc. 1994;46(2):49-78. [Medline].

  19. Giovacchini RP. Abusing the volatile organic chemicals. Regul Toxicol Pharmacol. Mar 1985;5(1):18-37. [Medline].

  20. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, et al. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv. Jun 1998;49(6):812-5. [Medline].

  21. Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am. Mar 1998;25(1):153-67. [Medline].

  22. Kaplan HI, Sadhock BJ. Kaplan and Sadhock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 8th ed. Baltimore, Md: Williams & Wilkins; 1998:430-32.

  23. Korman M, Matthews RW, Lovitt R. Neuropsychological effects of abuse of inhalants. Percept Mot Skills. Oct 1981;53(2):547-53. [Medline].

  24. Kucuk NO, Kilic EO, Ibis E, et al. Brain SPECT findings in long-term inhalant abuse. Nucl Med Commun. Aug 2000;21(8):769-73. [Medline].

  25. Kurbat RS, Pollack CV Jr. Facial injury and airway threat from inhalant abuse: a case report. J Emerg Med. Mar-Apr 1998;16(2):167-9. [Medline].

  26. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents(1). J Adolesc Health. Mar 2001;28(3):170-80. [Medline].

  27. Lacy BW, Ditzler TF. Inhalant abuse in the military: an unrecognized threat. Mil Med. Apr 2007;172(4):388-92. [Medline].

  28. Maxwell JC. Deaths related to the inhalation of volatile substances in Texas: 1988-1998. Am J Drug Alcohol Abuse. Nov 2001;27(4):689-97. [Medline].

  29. McGarvey EL, Clavet GJ, Mason W, Waite D. Adolescent inhalant abuse: environments of use. Am J Drug Alcohol Abuse. Nov 1999;25(4):731-41. [Medline].

  30. Meadows R, Verghese A. Medical complications of glue sniffing. South Med J. May 1996;89(5):455-62. [Medline].

  31. Misra LK, Kofoed L, Fuller W. Treatment of inhalant abuse with risperidone. J Clin Psychiatry. Sep 1999;60(9):620. [Medline].

  32. Muilenburg JL, Johnson WD. Inhalant use and risky behavior correlates in a sample of rural middle school students. Subst Abus. Dec 2006;27(4):21-5. [Medline].

  33. National Conference of State Legislatures. Unpublished Information on Inhalation Legislation through June 2000.

  34. National Institute on Drug Abuse. Inhalant Abuse Research Report. 2005.

  35. National Institute on Drug Abuse and University of Michigan. Monitoring the Future 2005 Data From In-School Surveys of 8th-, 10th-, and 12th-Grade Students. Dec 2005.

  36. Office of National Drug Control Policy. Drug Policy Information Clearinghouse, Street Terms: Drugs and the Drug Trade Inhalations Section.

  37. Oh SJ, Kim JM. Giant axonal swelling in "huffer's" neuropathy. Arch Neurol. Aug 1976;33(8):583-6. [Medline].

  38. Russe BR, McCoy CB, Barton JE. Recent findings concerning inhalant use. Chem Depend. 1980;4(1-2):113-26. [Medline].

  39. Santos de Barona M, Simpson DD. Inhalant users in drug abuse prevention programs. Am J Drug Alcohol Abuse. 1984;10(4):503-18. [Medline].

  40. Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry. Apr 13 2007;31(3):769-71. [Medline].

  41. Soderberg LS. Immunomodulation by nitrite inhalants may predispose abusers to AIDS and Kaposi's sarcoma. J Neuroimmunol. Mar 15 1998;83(1-2):157-61. [Medline].

  42. Weintraub E, Gandhi D, Robinson C. Medical complications due to mothball abuse. South Med J. Apr 2000;93(4):427-9. [Medline].

  43. Wu LT, Ringwalt CL. Inhalant use and disorders among adults in the United States. Drug Alcohol Depend. Oct 15 2006;85(1):1-11. [Medline].

  44. Young SJ, Longstaffe S, Tenenbein M. Inhalant abuse and the abuse of other drugs. Am J Drug Alcohol Abuse. May 1999;25(2):371-5. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.